Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 1/20 | 0.67 |
| ▸ | HPGD | P15428 | 2/20 | 0.60 |
| ▸ | POLB | P06746 | 1/20 | 0.60 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.60 |
| ▸ | MAPK13 | O15264 | 3/20 | 0.58 |
| ▸ | MAPK12 | P53778 | 3/20 | 0.58 |
| ▸ | MAPK11 | Q15759 | 3/20 | 0.58 |
| ▸ | MAPK14 | Q16539 | 3/20 | 0.58 |
| ▸ | LMNA | P02545 | 4/20 | 0.58 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.58 |
| ▸ | GAA | P10253 | 2/20 | 0.57 |
| ▸ | RECQL | P46063 | 1/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.56 |
| ▸ | NTRK1 | P04629 | 2/20 | 0.56 |
| ▸ | NTRK2 | Q16620 | 1/20 | 0.56 |
| ▸ | NFE2 | Q16621 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1012719 | 0.80 | MAPK13 (0.78) | JAK2HPGDMAPK13MAPK12MAPK11 | |
| SCHEMBL1599957 | 0.79 | JAK2 (0.71) | JAK2HPGDMAPK13MAPK12MAPK11 | |
| SCHEMBL1600918 | 0.79 | MAPK14 (0.68) | JAK2HPGDMAPK13MAPK12MAPK11 | |
| SCHEMBL25793170 | 0.77 | MAPK13 (0.74) | JAK2MAPK13MAPK12MAPK11MAPK14 | |
| SCHEMBL5164195 | 0.76 | CDK8 (0.80) | JAK2MAPK13MAPK12MAPK11MAPK14 | |
| SCHEMBL25801441 | 0.76 | JAK2 (0.63) | JAK2HPGDMAPK13MAPK12MAPK11 | |
| SCHEMBL1599299 | 0.75 | MAPK14 (0.63) | JAK2HPGDPOLBMAPK13MAPK12 | |
| SCHEMBL17488358 | 0.75 | MAPK13 (0.79) | JAK2MAPK13MAPK12MAPK11MAPK14 | |
| Hydrochloric Acid SCHEMBL29397175 | 0.75 | CDK8 (0.78) | JAK2MAPK13MAPK12MAPK11MAPK14 | |
| SCHEMBL1600606 | 0.75 | MAPK14 (0.66) | JAK2HPGDMAPK13MAPK12MAPK11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170000768-A1 | COMPOSITIONS AND METHODS RELATING TO HEAT SHOCK TRANSCRIPTION FACTOR ACTIVATING COMPOUNDS AND TARGETS THEREOF | CHAPERONE THERAPEUTICS, INC. | 2017-01-05 | — | — | US | claimed |
| US-20160221958-A1 | SUBSTITUTED PYRAZOLES AS HEAT SHOCK TRANSCRIPTION FACTOR ACTIVATORS | DUKE UNIVERSITY | 2016-08-04 | — | — | US | claimed |
| US-20130267543-A1 | COMPOSITIONS AND METHODS RELATING TO HEAT SHOCK TRANSCRIPTION FACTOR ACTIVATING COMPOUNDS AND TARGETS THEREOF | CHAPERONE THERAPEUTICS, INC. (US) | 2013-10-10 | — | — | US | claimed |
| EP-2637658-A1 | COMPOSITIONS AND METHODS RELATING TO HEAT SHOCK TRANSCRIPTION FACTOR ACTIVATING COMPOUNDS AND TARGETS THEREOF | Duke University (US) | 2013-09-18 | — | — | EP | claimed |
| WO-2012064715-A1 | COMPOSITIONS AND METHODS RELATING TO HEAT SHOCK TRANSCRIPTION FACTOR ACTIVATING COMPOUNDS AND TARGETS THEREOF | DUKE UNIVERSITY (US) | 2012-05-18 | — | — | WO | claimed |
| US-20110112073-A1 | COMPOSITIONS AND METHODS RELATING TO HEAT SHOCK TRANSCRIPTION FACTOR ACTIVATING COMPOUNDS AND TARGETS THEREOF | DUKE UNIVERSITY (US) | 2011-05-12 | — | — | US | claimed |
| US-9718784-B2 | Substituted pyrazoles as heat shock transcription factor activators | DUKE UNIVERSITY (US) | 2017-08-01 | — | — | US | disclosed |
| US-9717709-B2 | Substituted pyrazoles as heat shock transcription factor activators | DUKE UNIVERSITY (US) | 2017-08-01 | — | — | US | disclosed |
| US-20170000768-A1 | COMPOSITIONS AND METHODS RELATING TO HEAT SHOCK TRANSCRIPTION FACTOR ACTIVATING COMPOUNDS AND TARGETS THEREOF | CHAPERONE THERAPEUTICS, INC. | 2017-01-05 | — | — | US | disclosed |
| US-9447058-B2 | Substituted 1,3-thiazoles as heat shock transcription factor 1 activators | DUKE UNIVERSITY (US) | 2016-09-20 | — | — | US | disclosed |
| US-20160221958-A1 | SUBSTITUTED PYRAZOLES AS HEAT SHOCK TRANSCRIPTION FACTOR ACTIVATORS | DUKE UNIVERSITY | 2016-08-04 | — | — | US | disclosed |
| US-9315449-B2 | Substituted pyrazoles as heat shock transcription factor activators | DUKE UNIVERSITY (US) | 2016-04-19 | — | — | US | disclosed |
| US-20160024035-A1 | COMPOSITIONS AND METHODS RELATING TO HEAT SHOCK TRANSCRIPTION FACTOR ACTIVATING COMPOUNDS AND TARGETS THEREOF | DUKE UNIVERSITY | 2016-01-28 | — | — | US | disclosed |
| US-9156775-B2 | Substituted 1,3-thiazoles as heat shock transcription factor 1 activators | DUKE UNIVERSITY (US) | 2015-10-13 | — | — | US | disclosed |
| US-20130267543-A1 | COMPOSITIONS AND METHODS RELATING TO HEAT SHOCK TRANSCRIPTION FACTOR ACTIVATING COMPOUNDS AND TARGETS THEREOF | CHAPERONE THERAPEUTICS, INC. (US) | 2013-10-10 | — | — | US | disclosed |
| EP-2637658-A1 | COMPOSITIONS AND METHODS RELATING TO HEAT SHOCK TRANSCRIPTION FACTOR ACTIVATING COMPOUNDS AND TARGETS THEREOF | Duke University (US) | 2013-09-18 | — | — | EP | disclosed |
| WO-2012064715-A1 | COMPOSITIONS AND METHODS RELATING TO HEAT SHOCK TRANSCRIPTION FACTOR ACTIVATING COMPOUNDS AND TARGETS THEREOF | DUKE UNIVERSITY (US) | 2012-05-18 | — | — | WO | disclosed |
| US-20110112073-A1 | COMPOSITIONS AND METHODS RELATING TO HEAT SHOCK TRANSCRIPTION FACTOR ACTIVATING COMPOUNDS AND TARGETS THEREOF | DUKE UNIVERSITY (US) | 2011-05-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160221958-A1 | SUBSTITUTED PYRAZOLES AS HEAT SHOCK TRANSCRIPTION FACTOR ACTIVATORS | HSF1, HSP90AB1, HSPBP1 | JAK2 3542/4885HPGD 698/4885POLB 3166/4885 |
| US-20160024035-A1 | COMPOSITIONS AND METHODS RELATING TO HEAT SHOCK TRANSCRIPTION FACTOR ACTIVATING COMPOUNDS AND TARGETS THEREOF | HSF1, HSP90AB1, HSPBP1 | JAK2 3503/4885HPGD 1054/4885POLB 2933/4885 |
| US-20110112073-A1 | COMPOSITIONS AND METHODS RELATING TO HEAT SHOCK TRANSCRIPTION FACTOR ACTIVATING COMPOUNDS AND TARGETS THEREOF | HSF1, HSP90AB1, HSPBP1 | JAK2 3503/4885HPGD 1054/4885POLB 2933/4885 |
| US-20130267543-A1 | COMPOSITIONS AND METHODS RELATING TO HEAT SHOCK TRANSCRIPTION FACTOR ACTIVATING COMPOUNDS AND TARGETS THEREOF | HSF1, HSP90AB1, HSPBP1 | JAK2 3503/4885HPGD 1054/4885POLB 2933/4885 |
| US-20170000768-A1 | COMPOSITIONS AND METHODS RELATING TO HEAT SHOCK TRANSCRIPTION FACTOR ACTIVATING COMPOUNDS AND TARGETS THEREOF | HSF1, HSP90AB1, HSPBP1 | JAK2 3503/4885HPGD 1054/4885POLB 2933/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.